



DUR BOARD MEETING

February 10, 2010

6:00 p.m.



AGENDA ITEM NO. 5

VOTE TO PRIOR AUTHORIZE ATYPICAL ANTIPSYCHOTICS

Presented by: Shellie Keast, Pharm.D., M.S.



Education Plan




Advocates

- Training with Groups
- Press Release

Members

- Newsletter
- Press Release
- Advocate Seminars



Providers

Global Announcements

- Web Banner
- Fax Blasts
- Web Alerts
- Global Message
- Web FAQ
- Press Release

Targeted Messages

- Mailed Letter
- Outbound calls
- Enhanced Fax Backs (PA)

Training Sessions

- Community Mental Health Center Leaders
- Institutional Leaders



Timeline

February

- 10th - DUR Vote
- 11th - Contracts Mailed

March

- 11th - OHCA Board Meeting
- 12th - Contracts Due
- Week of 15th - Global Announcements
- Week of 22nd - Letters Mailed, Training Sessions

April

- 1st - Implementation
- 15th - Questionnaires Mailings Begin



Changes to Criteria Since January Meeting

- Added: Requests for unusual dosing or indications will be referred to the OHCA-contracted psychiatrist for review.
- Removed: FDA indicated diagnosis
- Rearranged wording in criteria to three subheadings: Current Users, Clinical Conditions, Step Therapy
- Clearly defined criteria following release from inpatient facility.



Proposed Tier List

Atypical Antipsychotics*

Tier 1	Tier 2	Tier 3 [†]
risperidone (Risperdal®) clozapine (Clozaril®)	Supplemental Rebated Tier-3 medications	olanzapine (Zyprexa®) quetiapine (Seroquel®) ziprasidone (Geodon®) aripiprazole (Abilify®) paliperidone (Invega®) quetiapine ER (Seroquel XR®) asenapine (Saphris®) clozapine (Fazaclo®) olanzapine/fluoxetine (Symbyax®) iloperidone (Fanapt™)

